WIXOM, Mich. / Feb 16, 2023 / Business Wire / Rockwell Medical, Inc. (Nasdaq:RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2022 on Thursday, March 30, 2023. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET.
CONFERENCE CALL AND WEBCAST DETAILS
Date: Thursday, March 30, 2023
Time: 8:00am ET
Webcast: www.RockwellMed.com/Results
Live Number: (888) 660-6347 // (International) 1 (929) 201-6594
Replay Number: (800) 770-2030 // (International) 1 (647) 362-9199
A replay will be available via the replay number and webcast through April 29, 2023.
Access Code: 4944610
Speakers:
Format: Discussion of fourth quarter and full-year 2022 operational and financial results followed by Q&A.
About Rockwell Medical
Rockwell Medical, Inc. (Nasdaq: RMTI) is a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney. Rockwell is an innovative leader in producing and delivering a portfolio of hemodialysis products, including concentrates (solutions and powders) and related ancillaries, to dialysis providers in the United States and internationally. Rockwell is the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States. The Company is dedicated to providing the hemodialysis community with the highest quality products supported by the most reliable delivery service in the industry. For more information, visit www.RockwellMed.com.
| Last Trade: | US$1.08 |
| Daily Change: | -0.01 -0.92 |
| Daily Volume: | 354,334 |
| Market Cap: | US$37.180M |
October 28, 2025 September 30, 2025 August 14, 2025 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load